7 research outputs found
SITC/iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools - a compass in the land of biomarker discovery
No full textRecent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to
provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are
durable, dramatically extending survival. Extensive research efforts are being made to identify and validate
biomarkers that can help identify subsets of cancer patients that will benefit most from these novel
immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are
playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This
Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly
the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources
relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were
identified by experts in the field who are actively pursuing research in biomarker identification and validation. This
organized collection of the most useful references, online resources and tools serves as a compass to guide
discovery of biomarkers essential to advancing novel cancer immunotherapies
Presence 2021
No full textMary Ann B. Miller
Lois Roma-Deeley
Marjorie Maddox
Gregory Orfalea
Jeannine M. Pitas
Reginald Baylor
Joseph A. Brown, S.J.
Ashaq Hussain Parray
Barbar Crooker
Dante Di Stafano
Linda Nemec Foster
Mary Ladany
Kelli Russell Agodon
Sarah Allen
Lisa Ampleman
Matthew J. Andrews
Devon Balwit
Charles Baudelaire
Lisa Breger
Ronda Piszk Broatch
Mary Buchinger
Justin Carisio
Katy Carl
Sean M. Conrey
Robert Cording
Sarah Cortez
Zach Czaia
Cortney Davis
John F. Deane
CX Dillhunt
Lynn Domina
Christina Ellsberg
CJ Giroux
George Guida
Maryanne Hannan
Marc Harshman
Matthew E. Henry
Lou Ella Hickman, IWBS
John Hodgen
Juan Ramon JImenez
Kirsten Kinnell
Leonard Kress
Kristina Kryukova
Gerry LaFemina
K. T. Landon
Sheree La Puma
Sue Fagalde Lick
James Littwin
V. P. Loggins
Jimmy Long
Dan MacIsaac
Annita Costa Malufe
John Martone
Jane McCafferty
Megan McDermott
Julio Martinez Mesanza
Gabriela Mistral
Theresa Monteiro
J. P. Murphy
Ann Neelon
Colin Pope
Rainer Maria Rilke
Susan McLean
James Owens
Lisa Toth Salinas
Nicholas Samaras
Julia Samorodova
J. D. Schraffenberger
Martha Silano
Katherine Smith
Maria Terrone
David Thoreen
Daniel Tobin
Cindy Veach
Shanna Powlus Wheeler
James Matthew Wilson
Jessica Schnepp
Mary Szybist
Madeleine Mysko
Carol Park
Ned Balbo
Kevin Brown
Jeannine M. Pitas
Sheryl St. Germain
Michael P. Murphy
Marion Goldstein
Robert Cording
Donna Dzurilla
William Coleman
Janet McCann
Isak Bond
Ryan Wilson
Maryann Corbett
Jessica Hooton Wilson
Wendy Galgan
Mia Schilling Grogan
Janna Schledorn
Julie L. Moore
Carole Stone
Laura Hogan
Alan Berecka
Janine Molinaro Bayer
Owen Lewishttps://griffinshare.fontbonne.edu/presence/1004/thumbnail.jp
the International Society for Biological Therapy
No full textGuiding cancer immunotherapy from bench to bedside Review of the 25th annual scientific meeting o
The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program
No full textAbstract The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade, the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancer™ in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1, 2010 in Washington, D.C. as part of the educational offerings associated with the society's 25th anniversary. The target audience was basic and clinical investigators from academia, industry and regulatory agencies, and included clinicians, post-doctoral fellows, students, and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in tumor immunology and clinical/translational caner immunology. Ten prominent investigators presented on the following topics: innate immunity and inflammation; an overview of adaptive immunity; dendritic cells; tumor microenvironment; regulatory immune cells; immune monitoring; cytokines in cancer immunotherapy; immune modulating antibodies; cancer vaccines; and adoptive T cell therapy. Presentation slides, a Primer webinar and additional program information are available online on the society's website.</p
Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
No full textAbstract The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.</p
Review of the 25<sup>th </sup>annual scientific meeting of the International Society for Biological Therapy of Cancer
No full textAbstract Led by key opinion leaders in the field, the 25th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) provided a scientific platform for ~500 attendees to exchange cutting-edge information on basic, clinical, and translational research in cancer immunology and immunotherapy. The meeting included keynote addresses on checkpoint blockade in cancer therapy and recent advances in therapeutic vaccination against cancer induced by Human Papilloma Virus 16. Participants from 29 countries interacted through oral presentations, panel discussions, and posters on topics that included dendritic cells and cancer, targeted therapeutics and immunotherapy, innate/adaptive immune interplay in cancer, clinical trial endpoints, vaccine combinations, countering negative regulation, immune cell trafficking to tumor microenvironment, and adoptive T cell transfer. In addition to the 50 oral presentations and >180 posters on these topics, a new SITC/iSBTc initiative to create evidence-based Cancer Immunotherapy Guidelines was announced. The SITC/iSBTc Biomarkers Taskforce announced the release of recommendations on immunotherapy biomarkers and a highly successful symposium on Immuno-Oncology Biomarkers that took place on the campus of the National Institutes of Health (NIH) immediately prior to the Annual Meeting. At the Annual Meeting, the NIH took the opportunity to publicly announce the award of the U01 grant that will fund the Cancer Immunotherapy Trials Network (CITN). In summary, the Annual Meeting gathered clinicians and scientists from academia, industry, and regulatory agencies from around the globe to interact and exchange important scientific advances related to tumor immunobiology and cancer immunotherapy.</p
